JP2020517645A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517645A5 JP2020517645A5 JP2019556913A JP2019556913A JP2020517645A5 JP 2020517645 A5 JP2020517645 A5 JP 2020517645A5 JP 2019556913 A JP2019556913 A JP 2019556913A JP 2019556913 A JP2019556913 A JP 2019556913A JP 2020517645 A5 JP2020517645 A5 JP 2020517645A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- oligonucleotide
- composition according
- bond
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487425P | 2017-04-19 | 2017-04-19 | |
| US62/487,425 | 2017-04-19 | ||
| PCT/US2018/028308 WO2018195281A1 (en) | 2017-04-19 | 2018-04-19 | P-ethoxy nucleic acids for igf-1r inhibition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020517645A JP2020517645A (ja) | 2020-06-18 |
| JP2020517645A5 true JP2020517645A5 (https=) | 2021-05-27 |
Family
ID=63856055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556913A Pending JP2020517645A (ja) | 2017-04-19 | 2018-04-19 | Ｉｇｆ−１ｒ阻害のためのｐ−エトキシ核酸 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200038429A1 (https=) |
| EP (1) | EP3628003A4 (https=) |
| JP (1) | JP2020517645A (https=) |
| KR (1) | KR20200021453A (https=) |
| CN (1) | CN111447922A (https=) |
| AU (1) | AU2018254485B2 (https=) |
| CA (1) | CA3060090A1 (https=) |
| MX (1) | MX2019012493A (https=) |
| WO (1) | WO2018195281A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2982205A1 (en) | 2015-04-10 | 2016-10-13 | David W. Andrews | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes |
| EP3362563A1 (en) | 2015-10-14 | 2018-08-22 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for liposomal formulation |
| JP7132911B2 (ja) | 2016-09-16 | 2022-09-07 | バイオ－パス ホールディングス， インコーポレイテッド | リポソームアンチセンスオリゴヌクレオチドとの併用療法 |
| EP3612160A4 (en) | 2017-04-19 | 2021-01-20 | Bio-Path Holdings, Inc. | P-ETHOXY NUCLEIC ACIDS FOR BCL2 INHIBITION |
| IL269608B2 (en) | 2017-04-19 | 2024-06-01 | Bio Path Holdings Inc | Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease |
| AU2019372132A1 (en) * | 2018-11-02 | 2021-06-03 | Thomas Jefferson University | Methods and compositions for treating breast cancer using antisense |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6340674B1 (en) | 1993-03-26 | 2002-01-22 | Thomas Jefferson University | Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides |
| US6015886A (en) * | 1993-05-24 | 2000-01-18 | Chemgenes Corporation | Oligonucleotide phosphate esters |
| US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US7704962B1 (en) * | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
| US20030180789A1 (en) * | 1998-12-30 | 2003-09-25 | Dale Roderic M.K. | Arrays with modified oligonucleotide and polynucleotide compositions |
| EP1432724A4 (en) * | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
| US9150605B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| CN106714547B (zh) | 2014-07-17 | 2020-12-18 | 飞利浦灯具控股公司 | 园艺照明装置 |
| CA2982205A1 (en) * | 2015-04-10 | 2016-10-13 | David W. Andrews | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes |
| EP3362563A1 (en) | 2015-10-14 | 2018-08-22 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for liposomal formulation |
-
2018
- 2018-04-19 JP JP2019556913A patent/JP2020517645A/ja active Pending
- 2018-04-19 US US16/606,377 patent/US20200038429A1/en not_active Abandoned
- 2018-04-19 AU AU2018254485A patent/AU2018254485B2/en active Active
- 2018-04-19 CA CA3060090A patent/CA3060090A1/en active Pending
- 2018-04-19 KR KR1020197034170A patent/KR20200021453A/ko not_active Ceased
- 2018-04-19 MX MX2019012493A patent/MX2019012493A/es unknown
- 2018-04-19 EP EP18788289.9A patent/EP3628003A4/en not_active Withdrawn
- 2018-04-19 CN CN201880036079.XA patent/CN111447922A/zh active Pending
- 2018-04-19 WO PCT/US2018/028308 patent/WO2018195281A1/en not_active Ceased
-
2021
- 2021-11-18 US US17/530,051 patent/US12472199B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517645A5 (https=) | ||
| Liu et al. | Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles | |
| Gissot et al. | Nucleoside, nucleotide and oligonucleotide based amphiphiles: a successful marriage of nucleic acids with lipids | |
| Yin et al. | RNA micelles for the systemic delivery of anti-miRNA for cancer targeting and inhibition without ligand | |
| ES2924806T3 (es) | Análogos de 4'-fosfato y oligonucleótidos que comprenden el mismo | |
| Couvreur et al. | Nanotechnologies for drug delivery: Application to cancer and autoimmune diseases | |
| JP2020517632A5 (https=) | ||
| Vandghanooni et al. | Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective | |
| JP5906327B2 (ja) | 磁性ナノ粒子−ＳＡＭｉＲＮＡ複合体およびその製造方法 | |
| CN112107693A (zh) | 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途 | |
| CN105051205B (zh) | 鉴定生物标记物、治疗靶点或治疗试剂的高通量筛选方法 | |
| WO2010040091A1 (en) | Novel dna nanostructures that promote cell-cell interaction and use thereof | |
| Nam et al. | Size-controlled synthesis of polymerized DNA nanoparticles for targeted anticancer drug delivery | |
| IL269608B2 (en) | Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease | |
| CN105705638A (zh) | 改善的具有高效能的纳米颗粒型寡核苷酸结构及其制备方法 | |
| US20200405649A1 (en) | Dna origami nanoparticle delivery of programmed chromosome breakage machinery | |
| CN102458379B (zh) | 基于官能两亲分子或大分子的具有多隔室的配制剂 | |
| Xiong et al. | Engineered Aptamer‐Organic Amphiphile Self‐Assemblies for Biomedical Applications: Progress and Challenges | |
| JP2020517646A5 (https=) | ||
| Senanayake et al. | Novel anticancer polymeric conjugates of activated nucleoside analogues | |
| Mahdieh et al. | Novel polyurethane-based ionene nanoparticles electrostatically stabilized with hyaluronic acid for effective gene therapy | |
| Tan et al. | Designer tridentate mucin 1 aptamer for targeted drug delivery | |
| KR20170054429A (ko) | 치료용 나노입자 및 관련 조성물, 방법, 및 시스템 | |
| WO2017162185A1 (zh) | 对非小细胞肺癌具有抑制作用的核糖核酸适配体及包含其的药物组合物 | |
| JP2024508119A (ja) | Ｒｎａｉコンジュゲートおよびその使用 |